Why Is PTC THERAPEUTICS INC (PTCT) Stock Moving Today?

PTCT stock is down 8.74% to $68.92 in a session marked by a sharp decline from its opening price. The stock opened with a 0.9% gap down and quickly dropped to a low of $64.57 before trading closed at $68.92. The move follows the company’s second-quarter 2026 earnings report and a corporate update that included a raised sales forecast, but also a leadership change and mixed analyst reactions.

What Happened

PTC Therapeutics reported Q2 2026 results with total revenue of $361 million, including $239 million in product revenue. The company raised its full-year 2026 total revenue guidance to $1.18 billion to $1.28 billion. However, the 8-K filing disclosed the departure of a director and the appointment of certain officers, signaling internal changes. The earnings call, held on July 30, 2026, featured comments from company executives, but the market reacted negatively, with the stock falling sharply during the session. The PR Newswire announcement highlighted the robust Q2 performance, but the broader market response was bearish, as reflected in the intraday price action.

What The Data Shows

The stock opened at $74.85 and fell to $64.57, a level not seen since early August. Volume so far is 0.9 million shares, which is 0.5 times the 3-month daily average. The stock is currently trading within its 52-week range of $43.17 to $90.87. Recent insider transactions include 14 sales totaling $16.6 million in the last 90 days, with the most recent filing on July 16. Congressional trades include two recent purchases by Donald J. Trump in March and February 2026, and a sale in January.

What To Watch

The stock is set to continue trading with elevated volatility. Investors should monitor the company’s upcoming earnings and any further leadership developments. Analyst coverage remains mixed, with Wells Fargo and Cantor Fitzgerald maintaining overweight ratings while RBC Capital maintains a sector perform rating.